Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18).

Cureus · 2025 · PMC12131103 · PMID 40462821

Europe PMC DOI

hedged sentences

0.2290

closest p · 4.6× alpha

0.2290

boldest claim

The sentences

did not reach statistical significancep=0.229not close (p > 0.1)

However, this difference did not reach statistical significance (p=0.229).

also in 111,027 other papers

showed a trendno p-value reported

Conclusions: In this real-world, 18-month cohort, empagliflozin produced more pronounced improvements in albuminuria and a slightly greater absolute reduction in HbA1c, whereas semaglutide showed a trend toward greater weight loss, though not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.